Institution · German Inflammatory Bowel Diseases Study Group

Most cited papers from German Inflammatory Bowel Diseases Study Group

German Inflammatory Bowel Diseases Study Group

What are the most cited papers from German Inflammatory Bowel Diseases Study Group?

The most cited paper from German Inflammatory Bowel Diseases Study Group is "Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia" (Hermann Schulz, 2002), with 206 citations. Next come "Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma" (175) and "Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma" (159).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 17 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia Hermann Schulz · Blood	12 Jul 2002	206
2	Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma Paul Jan Bröckelmann et al. · JAMA Oncology Open access	30 Apr 2020	175
3	Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma L Boudová, Emina Torlakovic, Jan Delabie et al. · Blood	29 Jul 2003	159
4	Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant Sally Arai, Michelle A. Fanale, Sven deVos et al. · Leukemia & lymphoma/Leukemia and lymphoma	26 Apr 2013	141
5	Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group Dennis Alexander Eichenauer, Indra Thielen, Heinz Haverkamp et al. · Blood	30 Jan 2014	141
6	Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial Peter Borchmann et al. · The Lancet Open access	Jul 2024	139
7	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota Natali Pflug, Sandra Kluth, Jörg Janne Vehreschild et al. · OncoImmunology Open access	22 Apr 2016	124
8	Lymphocyte-Rich Classical Hodgkin's Lymphoma: Clinical Presentation and Treatment Outcome in 100 Patients Treated Within German Hodgkin's Study Group Trials Alexander Shimabukuro‐Vornhagen, Heinz Haverkamp, Andreas Engert et al. · Journal of Clinical Oncology Open access	12 Jul 2005	103
9	Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma Boris Böll, Henning Bredenfeld, Helen Görgen et al. · Blood Open access	15 Sep 2011	96
10	Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group Peter Borchmann et al. · The Lancet Oncology	22 Feb 2017	90
11	Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. Markus W. Loeffler et al. · Journal of Clinical Oncology	Jun 1997	86
12	14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group M. Sieber, Henning Bredenfeld, Andreas Josting et al. · Journal of Clinical Oncology	29 Apr 2003	85
13	Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma Jing Ouyang, Annette Plütschow, Elke Pogge von Strandmann et al. · Blood Open access	27 Feb 2013	82
14	Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone Eckhart Dühmke, Volker Diehl, Markus W. Loeffler et al. · International Journal of Radiation OncologyBiologyPhysics	Sep 1996	81
15	In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection Sophia Sobesky et al. · Med Open access	Oct 2021	74
16	Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high‐risk B‐cell chronic lymphocytic leukemia Birgit Kainz, Medhat M. Shehata, Martin Bilban et al. · International Journal of Cancer	9 Jul 2007	69
17	Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management Dennis Alexander Eichenauer, Andreas Engert · Hematology Open access	8 Dec 2017	67
18	AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial Stephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow et al. · Leukemia & lymphoma/Leukemia and lymphoma	3 Jul 2022	61
19	Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group Beate Klimm, H.T. Eich, Heinz Haverkamp et al. · Annals of Oncology Open access	28 Oct 2006	59
20	Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma Carsten Kobe, Helen Goergen, Christian Baues et al. · Blood Open access	30 Aug 2018	56
21	Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin's Lymphoma: Final Results of the German Hodgkin's Lymphoma Study Group Trial HD5 M. Sieber · Journal of Clinical Oncology	15 Jan 2002	55
22	Predicting dementia in primary care patients with a cardiovascular health metric: a prospective population-based study Johannes Baltasar Hessler-Kaufmann, Karl‐Heinz Ander, Monika Brönner et al. · BMC Neurology Open access	26 Jul 2016	54
23	Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG) Teresa Veronika Halbsguth, Lucia Nogová, Horst Mueller et al. · Blood	16 Jun 2010	53
24	FDG–PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value Jana Marková, Carsten Kobe, Magdaléna Skopalová et al. · Annals of Oncology Open access	19 Feb 2009	52
25	Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma Jan‐Michel Heger et al. · Journal of Clinical Oncology	30 Sep 2024	46
26	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia Tadeusz Robak, Andrzej Hellmann, Janusz S. Kloczko et al. · British Journal of Haematology Open access	15 Dec 2016	46
27	Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation Christian Baues, Simone Marnitz, Andreas Engert et al. · Radiation Oncology Open access	3 Jul 2018	43
28	Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL) Daniel C. Betticher, Giovanni Martinelli, John A. Radford et al. · Annals of Oncology Open access	3 Aug 2006	42
29	Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA Jan‐Michel Heger et al. · Blood	10 Nov 2023	40
30	A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia Claudia Trenkwalder et al. · Movement Disorders	15 Mar 2016	40
31	Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma Stephanie Sasse, Achim Rothe, Helen Goergen et al. · Leukemia & lymphoma/Leukemia and lymphoma	13 Feb 2013	40
32	Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers Felix Goeser, Barbara Sifft, Christoph K. Stein‐Thoeringer et al. · European Journal Of Haematology Open access	2 May 2021	39
33	Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma Stephanie Sasse, Beate Klimm, Helen Görgen et al. · Annals of Oncology Open access	6 Jul 2012	36
34	Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant Bastian von Tresckow, Horst Müller, Dennis Alexander Eichenauer et al. · Leukemia & lymphoma/Leukemia and lymphoma	21 Oct 2013	35
35	Quality of life assessment in Hodgkin’s disease: A new comprehensive approach Hans‐Henning Flechtner, Jens Ulrich Rüffer, Michel Henry-Amar et al. · Annals of Oncology Open access	1998	35
36	Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group Beate Klimm, Jeremy G. Franklin, Harald Stein et al. · Journal of Clinical Oncology Open access	13 Sep 2011	32
37	The translational science of hodgkin lymphoma Melita Cirillo, Sarah Reinke, Wolfram Klapper et al. · British Journal of Haematology	12 Nov 2018	31
38	Current status of prognostication in classical Hodgkin lymphoma Girish Venkataraman, M. Kamran Mirza, Dennis Alexander Eichenauer et al. · British Journal of Haematology	4 Feb 2014	31
39	The effect of Denmark Strait overflow on the Atlantic Meridional Overturning Circulation Frank Kösters, Rolf H. Käse, Andreas Schmittner et al. · Geophysical Research Letters	Feb 2005	28
40	Lymphocyte‐predominant and classical Hodgkin's lymphoma – comparison of outcomes Lucia Nogová, Thorsten Reineke, Andreas Josting et al. · European Journal Of Haematology	6 Jun 2005	28
41	BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial Philip C. Schouten, Oleg Gluz, Nadia Harbeck et al. · International Journal of Cancer Open access	6 Mar 2016	27
42	Radiotherapy Does Not Influence the Severe Pulmonary Toxicity Observed With the Administration of Gemcitabine and Bleomycin in Patients With Advanced-Stage Hodgkin's Lymphoma Treated With the BAGCOPP Regimen: A Report by the German Hodgkin's Lymphoma Study Group Andrew Macann, Henning Bredenfeld, Rolf‐Peter Müller et al. · International Journal of Radiation OncologyBiologyPhysics	13 Sep 2007	27
43	Advances in the treatment of Hodgkin lymphoma Dennis Alexander Eichenauer, Andreas Engert · International Journal of Hematology Open access	10 Oct 2012	25
44	Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison? Uwe Platzbecker, Ulrich Germing · Leukemia	6 May 2013	25
45	Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes Katrina Vanura, Trang Le, Harald Esterbauer et al. · Haematologica Open access	6 Oct 2008	25
46	Real‐world effectiveness of vedolizumab compared to anti‐TNF agents in biologic‐naïve patients with ulcerative colitis: A two‐year propensity‐score‐adjusted analysis from the prospective, observational VEDOIBD ‐study Bernd Bokemeyer, Sandra Plachta‐Danielzik, Romina di Giuseppe et al. · Alimentary Pharmacology & Therapeutics Open access	15 Jun 2023	24
47	Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group Sven Estenfelder, Eugen Tausch, Sandra Robrecht et al. · Blood	2 Dec 2016	24
48	The Past: What We Have Learned in the Last Decade Peter Borchmann, Andreas Engert · Hematology Open access	4 Dec 2010	24
49	Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies Volker Diehl, Michael Fuchs · Annals of Oncology Open access	Jul 2007	24
50	CT and MR imaging in Hodgkin's disease – present and future Axel Goßmann, Hans Theodor Eich, Andreas Engert et al. · European Journal Of Haematology Open access	6 Jun 2005	24

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.